Alnylam Pharmaceuticals Market Sentiment

Alnylam Pharmaceuticals Inc

ALNYNASDAQ

$155.94

-0.72-0.46%

Ult. Agg.: Nov 6, 7:45 PM

Panoramica Previsioni utili Eventi Obiettivi di prezzo Dati finanziariSentimentAzionariato Confronta Opzioni Rapporto azionario

Alnylam Pharmaceuticals Market Sentiment

Market sentiment signals for Alnylam Pharmaceuticals (ALNY): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▲ 6.5% short float

Options Flow▲ 0.87 P/C ratio

Insider Activity— N/A

Analyst Consensus

Buy

35 analysts

Options Flow (P/C)

0.87

More calls — Bullish

608 calls · 530 puts

Avg Consensus PT

$382

+146.0%

Highest Price Target

$583

+275.1%

Citigroup

Lowest Price Target

$199

+28.0%

Bernstein

Short Interest

6.5%

Declining — Bullish

Insider Activity (30d)

—

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Nov 2, 2026	Barclays	Eliana Merle—	+144.5%	$450 → $380	Maintained	Overweight
Nov 2, 2026	Truist Securities	Danielle Brill—	+44.8%	$315 → $225	Downgrade	Buy→Hold
Nov 2, 2026	Canaccord Genuity	Whitney Ijem—	+107.8%	$429 → $323	Maintained	Buy
Oct 30, 2026	UBS	Joon Lee—	+111.7%	$354 → $329	Maintained	Buy
Oct 30, 2026	TD Cowen	Ritu Baral—	+127.8%	$482 → $354	Maintained	Buy
Oct 30, 2026	Bernstein	Zhiqiang Shu—	+28.0%	$376 → $199	Downgrade	Outperform→Market Perform
Oct 30, 2026	Morgan Stanley	Michael Ulz—	+54.4%	$300 → $240	Maintained	Equal-Weight
Oct 30, 2026	Goldman Sachs	Salveen Richter—	+105.9%	$536 → $320	Maintained	Buy
Oct 30, 2026	Wells Fargo	Derek Archila—	+41.6%	$253 → $220	Maintained	Equal-Weight
Oct 30, 2026	RBC Capital	Luca Issi—	+80.2%	$345 → $280	Maintained	Outperform
Oct 30, 2026	Raymond James	Martin Auster—	+102.7%	$420 → $315	Downgrade	Strong Buy→Outperform
Oct 29, 2026	Needham	Joseph Stringer—	+56.3%	$357 → $243	Maintained	Buy
Oct 15, 2026	UBS	Joon Lee—	+127.8%	$550 → $354	Assumes	Buy
Oct 14, 2026	Citigroup	Eric Joseph—	+105.9%	$340 → $320	Maintained	Buy
Oct 14, 2026	Wells Fargo	Derek Archila—	+62.8%	$256 → $253	Maintained	Equal-Weight
Oct 8, 2026	RBC Capital	Luca Issi—	+122.0%	$350 → $345	Maintained	Outperform
Sep 30, 2026	JP Morgan	Jessica Fye—	+137.4%	$375 → $369	Maintained	Overweight
Sep 21, 2026	HC Wainwright & Co.	Patrick R. Trucchio—	+192.8%	$455 → $455	Maintained	Buy
Sep 8, 2026	Jefferies	Faisal Khurshid—	+67.3%	$230 → $260	Maintained	Hold
Sep 2, 2026	HC Wainwright & Co.	Patrick R. Trucchio—	+192.8%	$455 → $455	Maintained	Buy
Aug 19, 2026	BMO Capital	David Lebowitz—	+104.6%	$318	Initiate	Outperform
Aug 14, 2026	Wells Fargo	Derek Archila—	+64.7%	$316 → $256	Maintained	Equal-Weight
Aug 4, 2026	Truist Securities	Danielle Brill—	+102.7%	$410 → $315	Maintained	Buy
Aug 4, 2026	HC Wainwright & Co.	Patrick R. Trucchio—	+192.8%	$485 → $455	Maintained	Buy
Aug 3, 2026	Raymond James	Martin Auster—	+170.2%	$420 → $420	Upgrade	Outperform→Strong Buy

Alnylam Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Alnylam Pharmaceuticals Market Sentiment

Bulls vs Bears

Key Signals

Recent Analyst Actions

People Also Watch

Bulls vs Bears

People Also Watch